CE17 - Recherche translationnelle en santé


Submission summary

Corona virus disease 2019 (COVID19) is induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and caused over 5 million deaths world-wide in less than two years. Despite intense researches it is not clear how long last the immune responses against SARS-CoV-2 following infection or vaccination. Moreover, it is difficult to predict if current vaccine will protect from new SARS-CoV-2 variants At physiopathology standpoint COVID19 is characterized by a dysregulation of immune responses and metabolic pathways associated with an enhanced expression of LILRB1/MHC-I inhibitory axis that could account for these dysfunctions. Our main objective is to characterize the impact of blocking the LILRB1 / MHC-I interaction on immune responses, metabolism and viral replication. For this purpose, we will use a preclinical macaque model of SARS-CoV-2 infection. Overall, the data from this study could rapidly lead to the development of new clinical protocols aiming to improve the management of patients infected by SARS-CoV-2.

Project coordination

Benoit FAVIER (Département lnfectious Disease Models and lnnovative Therapies)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.


JOLIOT Institut des sciences du vivant FRÉDÉRIC-JOLIOT
IDMIT Département lnfectious Disease Models and lnnovative Therapies

Help of the ANR 441,737 euros
Beginning and duration of the scientific project: January 2023 - 36 Months

Useful links

Explorez notre base de projets financés



ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter